Exabis Library:

Welcome to the e-CCO Library!

Search by:

All Congress AbstractsCongress SlidesTools & SkillsVideos & Podcasts

Year: Category:

DOP052: Molecular response to Ustekinumab in moderate-to-severe Crohn’s Disease by serum protein and biopsy gene expression analysis: Results from Ustekinumab phase 3 studies

Year: 2017

Source: ECCO'17 Barcelona

Authors: Li K.

Crohn's disease, Ustekinumab, Immunology

Files: 1

DOP052: Ozanimod induces histological response and remission: results from the TOUCHSTONE study, a randomised, double-blind, placebo-controlled trial of ozanimod, an oral S1P receptor modulator, in moderate-to-severe ulcerative colitis

Year: 2016

Source: ECCO '16 Amsterdam

Authors:

W. Sandborn*¹, B. Feagan², G. D’Haens³, B. Levesque⁴, R. Pai⁵, S. Hanauer⁶, D. Wolf⁷, S. Vermeire⁸, S. Ghosh⁹, H. Smith¹⁰, M. Cravets¹⁰, P. Frohna¹⁰, S. Gujrathi¹⁰, R. Aranda¹⁰, A. Olson¹⁰

Created: Friday, 22 February 2019, 9:49 AM

DOP052: Ozanimod induces histological response and remission: results from the TOUCHSTONE study, a randomized, double-blind, placebo-controlled trial of ozanimod, an oral S1P receptor modulator, in moderate to severe ulcerative colitis

Year: 2016

Source: ECCO'16 DOP

Authors: Sandborn W.

Ulcerative Colitis, ozanimod

Files: 1

DOP052: Vedolizumab versus ustekinumab for Crohn's Disease: Comparative effectiveness in a real-life observational cohort study (ICC Case Series)

Year: 2018

Source: ECCO'18 Vienna

Authors: Biemans Vince

Created: Tuesday, 8 May 2018, 11:36 AM

Files: 1

DOP052: Vedolizumab vs. ustekinumab for Crohn’s disease: comparative effectiveness in a real-life observational cohort study (ICC case series)

Year: 2018

Source: ECCO '18 Vienna

Authors:

V. Biemans¹,²*, C. van der Woude³, A. van der Meulen - de Jong⁴, G. Dijkstra⁵, N. de Boer⁶, B. Oldenburg⁷, C. Ponsioen⁸, A. de Vries³, D. Wintjens², F. Hoentjen⁹, M. Pierik², Dutch Initiative on Crohn and Colitis (ICC)

Created: Thursday, 21 February 2019, 9:14 AM

DOP053: Effects of oral tofacitinib on patient-reported outcomes in patients with moderate to severe Crohn’s disease: Results of two Phase 2b randomized placebo-controlled trials

Year: 2016

Source: ECCO'16 DOP

Authors: Panés J.

Crohn's Disease, tofacitinib

Files: 1

DOP053: Effects of oral tofacitinib on patient-reported outcomes in patients with moderate-to-severe Crohn’s disease: results of 2 Phase 2b randomised placebo-controlled trials

Year: 2016

Source: ECCO '16 Amsterdam

Authors:

J. Panés*¹, M. Moscariello², E. Maller², G. Chan², W. Wang², P. Healey³

Created: Friday, 22 February 2019, 9:49 AM

DOP053: Impact of concomitant immunomodulator use on vedolizumab effectiveness: a multicentre consortium propensity score-matched analysis

Year: 2018

Source: ECCO '18 Vienna

Authors:

D. Hudesman¹, S. Chang¹, P. Shashi², A. Winters³, S. Chablaney³, J. Meserve⁴, A. Weiss⁵, S. Aniwan⁶, D. Faleck³, J.L. Koliani-Pace⁷, G. Kochhar², B. Boland⁴, S. Singh⁴, R. Hirten³, E. Shmidt³, K. Lasch⁸, M. Luo⁸, M. Bohm⁹, S. V Sagi⁹, M. Fischer⁹, D. Lukin⁵, K. Sultan¹⁰, A. Swaminath¹¹, N. Gupta¹², C.A. Siegel⁷, B. Shen², S. Kane⁶, E.V. Loftus⁶, B.E. Sands³, W.J. Sandborn⁴, J.-F. Colombel³, P.S. Dulai⁴*

Created: Thursday, 21 February 2019, 9:14 AM

DOP053: Impact of concomitant immunomodulator use on vedolizumab effectiveness: A multicentre consortium propensity score–matched analysis

Year: 2018

Source: ECCO'18 Vienna

Authors: Dulai Parambir S

Created: Tuesday, 8 May 2018, 11:36 AM

Files: 1

DOP053: The fecal microbiome as a tool for monitoring and predicting response outcomes in ustekinumab-treated, anti-TNFα refractory Crohn's disease patients: results from the CERTIFI study

Year: 2017

Source: ECCO '17 Barcelona

Authors:

Doherty M.K.^*1, Koumpouras C.¹, Telesco S.E.², Monast C.², Brodmerkel C.², Schloss P.D.¹

Created: Wednesday, 20 February 2019, 10:36 AM

DOP054: Discrepancies between patient-reported outcomes, endoscopic, and histologic appearance in ulcerative colitis

Year: 2016

Source: ECCO '16 Amsterdam

Authors:

J.-F. Colombel*¹, M. Keir², A. Scherl², R. Zhao², G. de Hertogh³, W. Faubion⁴, T. Lu²

Created: Friday, 22 February 2019, 9:49 AM

DOP054: High-throughput sequencing of T cell receptors from pediatric ulcerative colitis patients reveals distinct tissue-specific repertoires

Year: 2017

Source: ECCO '17 Barcelona

Authors:

Werner L.¹, Nunberg M.¹, Haberman Y.¹, Lahad A.¹, Turner D.², Weiss B.¹, Shouval D.^*1

Created: Wednesday, 20 February 2019, 10:36 AM

DOP054: Vedolizumab in combination with steroids for induction therapy in Crohn’s disease: an exploratory analysis of the GEMINI 2 and GEMINI 3 studies

Year: 2018

Source: ECCO '18 Vienna

Authors:

B.E. Sands¹, G. Van Assche², D. Tudor³, T. Tan⁴*

Created: Thursday, 21 February 2019, 9:14 AM

DOP054: Vedolizumab in combination with steroids for induction therapy in Crohn’s Disease: An exploratory analysis of the GEMINI 2 and GEMINI 3 studies

Year: 2018

Source: ECCO'18 Vienna

Authors: van Assche Gert

Created: Tuesday, 8 May 2018, 11:36 AM

Files: 1

DOP055: Azithromycin based therapy for induction of remission in mild to moderate active paediatric Crohn’s disease: the Multicentre azithromycin for Crohn’s disease AZCRO trial

Year: 2016

Source: ECCO '16 Amsterdam

Authors:

A. Levine*^{1, 2}, J. Kierkuś³, M. Kori⁴, M. Sladek⁵, R. Sigall Boneh¹, J. Escher⁶, E. Wine⁷, B. Yerushalmi⁸, J. Amil Dias⁹, R. Shaul¹⁰, A. Akriv¹¹, D. Zucker¹¹, D. Turner^{11, 12}

Created: Friday, 22 February 2019, 9:49 AM

DOP055: Luminal application of a GATA3-specific DNAzyme ameliorates mucosal inflammation in a randomised trial with active Ulcerative Colitis patients

Year: 2018

Source: ECCO'18 Vienna

Authors: Atreya Raja

Created: Tuesday, 8 May 2018, 11:36 AM

Files: 1

DOP055: Luminal application of a GATA3-specific DNAzyme ameliorates mucosal inflammation in a randomised trial with active ulcerative colitis patients

Year: 2018

Source: ECCO '18 Vienna

Authors:

R. Atreya¹*, T. Kühbacher²,³, H. Schmitt¹, S. Hirschmann¹, M.J. Waldner¹, O. Drvarov², S. Fischer¹, M. Vetter¹, B. Weigmann¹, A. Turowska⁴, T. Mühl⁴, U. Homburg⁴, J. Renz⁴, M. Vieth⁵, H. Garn⁶, H. Renz⁶, M.F. Neurath¹

Created: Thursday, 21 February 2019, 9:14 AM

DOP055: Results of the Fifth Scientific Workshop of the ECCO (II): clinical aspects of perianal fistulising Crohn's disease – the unmet needs

Year: 2017

Source: ECCO '17 Barcelona

Authors:

Gecse K.^*1, Sebastian S.², De Hertogh G.³, Yassin N.⁴, Kotze P.⁵, Reinisch W.⁶, Spinelli A.⁷, Koutroubakis I.⁸, Katsanos K.⁹, Hart A.¹⁰, van den Brink G.¹¹, Rogler G.¹², Bemelman W.¹³

Created: Wednesday, 20 February 2019, 10:36 AM

DOP055: Results of the Fifth Scientific Workshop of the ECCO (II): Clinical aspects of perianal fistulising Crohn’s Disease - The unmet needs

Year: 2017

Source: ECCO'17 Barcelona

Authors: Gecse K.

Last Modified: Friday, 21 May 2021, 12:32 PM by Admin User

MDT, Perianal disease, Perianal fistulae, Abscess

Files: 1

DOP056: Efficacy and safety of anti-fractalkine monoclonal antibody, E6011, in patients with Crohn’s disease who had lost response to anti-TNFα agents: A multicentre, open-label, Phase 1/2 study

Year: 2018

Source: ECCO '18 Vienna

Authors:

K. Matsuoka¹*, M. Naganuma², S. Tanida³, K. Kitamura⁴, T. Matsui⁵, M. Arai⁶, M. Fujiya⁷, N. Horiki⁸, H. Nebiki⁹, F. Kinjo¹⁰, T. Miyazaki¹¹, T. Matsumoto¹², M. Esaki¹³, K. Mitsuyama¹⁴, M. Saruta¹⁵, A. Ido¹⁶, S. Hojo¹⁷, O. Takenaka¹⁷, K. Oketani¹⁸, T. Imai¹⁹, H. Tsubouchi²⁰, T. Hibi²¹, T. Kanai²

Created: Thursday, 21 February 2019, 9:14 AM